UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 114

Sortiert nach

Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.4074-4074

2018

Volltextzugriff (PDF)

A phase Ib trial of ERK inhibition with ulixertinib combined with palbociclib in patients (Pts) with advanced solid tumors

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3103-3103

2021

Volltextzugriff (PDF)

Phase I study of hydroxychloroquine plus binimetinib in patients with metastatic pancreatic cancer (the HOPE trial)

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS634-TPS634

2022

Volltextzugriff (PDF)

Prognostic impact of cytomegalovirus (CMV) detection in colorectal cancer (CRC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e15120-e15120

2017

Volltextzugriff (PDF)

Characterization of the number and site of APC mutations in sporadic colorectal cancer

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.630-630

2017

Volltextzugriff (PDF)

Phase II single-arm study of palbociclib and cetuximab rechallenge in KRAS/NRAS/BRAF wild-type ( KRAS WT) metastatic colorectal cancer (mCRC) patients (pts)

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.88-88

2022

Volltextzugriff (PDF)

Cancer of unknown primary with gastrointestinal profiles: A distinct CUP subset

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3606-3606

2023

Volltextzugriff (PDF)

Molecular diagnostic classification for cancers of unknown primary (CUP): Post-testing diagnosis and treatment impact analysis from real-world claims data

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.6610-6610

2023

Volltextzugriff (PDF)

Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4173-TPS4173

2022

Volltextzugriff (PDF)

Clinical outcomes following termination of immunotherapy due to long-term benefit in MSI-H colorectal cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3585-3585

2022

Volltextzugriff (PDF)

Prognostic role of systemic inflammatory markers in patients with metastatic MSI-h/dMMR colorectal cancer receiving immunotherapy

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3524-3524

2022

Volltextzugriff (PDF)

Phase I study of mesenchymal stem cell (MSC)-derived exosomes with KRAS G12D siRNA in patients with metastatic pancreatic cancer harboring a KRAS G12D mutation

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS633-TPS633

2022

Volltextzugriff (PDF)

Phase II study of ipilimumab, nivolumab, and panitumumab in patients with KRAS / NRAS / BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.7-7

2021

Volltextzugriff (PDF)

A randomized phase II trial of MEK and CDK4/6 inhibitors vesus tipiracil/trifluridine (TAS-102) in metastatic KRAS/NRAS mutant (mut) colorectal cancer (CRC)

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.116-116

2022

Volltextzugriff (PDF)

Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3522-3522

2023

Volltextzugriff (PDF)

Association of KRAS and BRAF mutations with progression-free survival (PFS) with second-line FOLFIRI +/- regorafenib in metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.196-196

2020

Volltextzugriff (PDF)

Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable (MSS), BRAF V600E metastatic colorectal cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3598-3598

2022

Volltextzugriff (PDF)

RAS co-mutation and early onset disease represent an aggressive phenotype of atypical (non-V600) BRAF mutant metastatic colorectal cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3592-3592

2022

Volltextzugriff (PDF)

Outcomes of IBD-associated colorectal cancer and implications in early-onset colorectal cancer

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.22-22

2022

Volltextzugriff (PDF)

Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAF V600E metastatic colorectal cancer

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.12-12

2022

Volltextzugriff (PDF)

Longitudinal and personalized detection of circulating tumor DNA (ctDNA) for monitoring efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3531-3531

2020

Volltextzugriff (PDF)

Association of differential mucosal microbiome composition with clinicopathologic characteristics of rectal adenocarcinoma

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.656-656

2018

Volltextzugriff (PDF)

Association of consensus molecular subtypes (CMS) with time to progression (TTP), progression free survival (PFS), and overall survival (OS) with second-line FOLFIRI ± regorafenib in metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.597-597

2019

Volltextzugriff (PDF)

1 – 25 von 114

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(107)
Mit Volltextzugriff
(113)

Publikationsform

Sprache

Englisch
(114)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC)

A phase Ib trial of ERK inhibition with ulixertinib combined with palbociclib in patients (Pts) with advanced solid tumors

Phase I study of hydroxychloroquine plus binimetinib in patients with metastatic pancreatic cancer (the HOPE trial)

Prognostic impact of cytomegalovirus (CMV) detection in colorectal cancer (CRC)

Characterization of the number and site of APC mutations in sporadic colorectal cancer

Phase II single-arm study of palbociclib and cetuximab rechallenge in KRAS/NRAS/BRAF wild-type ( KRAS WT) metastatic colorectal cancer (mCRC) patients (pts)

Cancer of unknown primary with gastrointestinal profiles: A distinct CUP subset

Molecular diagnostic classification for cancers of unknown primary (CUP): Post-testing diagnosis and treatment impact analysis from real-world claims data

Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors

Clinical outcomes following termination of immunotherapy due to long-term benefit in MSI-H colorectal cancer

Prognostic role of systemic inflammatory markers in patients with metastatic MSI-h/dMMR colorectal cancer receiving immunotherapy

Phase I study of mesenchymal stem cell (MSC)-derived exosomes with KRAS G12D siRNA in patients with metastatic pancreatic cancer harboring a KRAS G12D mutation

Phase II study of ipilimumab, nivolumab, and panitumumab in patients with KRAS / NRAS / BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC)

A randomized phase II trial of MEK and CDK4/6 inhibitors vesus tipiracil/trifluridine (TAS-102) in metastatic KRAS/NRAS mutant (mut) colorectal cancer (CRC)

Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program

Association of KRAS and BRAF mutations with progression-free survival (PFS) with second-line FOLFIRI +/- regorafenib in metastatic colorectal cancer (mCRC)

Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable (MSS), BRAF V600E metastatic colorectal cancer

RAS co-mutation and early onset disease represent an aggressive phenotype of atypical (non-V600) BRAF mutant metastatic colorectal cancer

Outcomes of IBD-associated colorectal cancer and implications in early-onset colorectal cancer

Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAF V600E metastatic colorectal cancer

Longitudinal and personalized detection of circulating tumor DNA (ctDNA) for monitoring efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC)

Association of differential mucosal microbiome composition with clinicopathologic characteristics of rectal adenocarcinoma

Association of consensus molecular subtypes (CMS) with time to progression (TTP), progression free survival (PFS), and overall survival (OS) with second-line FOLFIRI ± regorafenib in metastatic colorectal cancer (mCRC)

Suchergebnisse filtern